Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“From immunotherapy (IO) failures to new strategies and biotech innovations in metastatic TNBC, to IO timing, chemo backbones, and novel approaches in the early stage.
All this and more in our latest review on immune checkpoint inhibitors in TNBC”
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
Authors: Chiara Corti, Beyza Koca, Tasnim Rahman, Elizabeth A Mittendorf, Sara M Tolaney
More posts featuring Chiara Corti.
